These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11679463)

  • 1. Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes.
    Meneilly GS; McIntosh CH; Pederson RA; Habener JF; Gingerich R; Egan JM; Finegood DT; Elahi D
    Diabetes Care; 2001 Nov; 24(11):1951-6. PubMed ID: 11679463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes.
    Meneilly GS; McIntosh CH; Pederson RA; Habener JF; Gingerich R; Egan JM; Elahi D
    J Gerontol A Biol Sci Med Sci; 2001 Nov; 56(11):M681-5. PubMed ID: 11682575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia.
    Ryan AS; Egan JM; Habener JF; Elahi D
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2399-404. PubMed ID: 9661618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
    Toft-Nielsen MB; Madsbad S; Holst JJ
    Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
    Elahi D; McAloon-Dyke M; Fukagawa NK; Meneilly GS; Sclater AL; Minaker KL; Habener JF; Andersen DK
    Regul Pept; 1994 Apr; 51(1):63-74. PubMed ID: 8036284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.
    Nauck MA; Weber I; Bach I; Richter S; Orskov C; Holst JJ; Schmiegel W
    Diabet Med; 1998 Nov; 15(11):937-45. PubMed ID: 9827848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.
    Egan JM; Meneilly GS; Habener JF; Elahi D
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3768-73. PubMed ID: 12161508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
    Nauck MA; Kleine N; Orskov C; Holst JJ; Willms B; Creutzfeldt W
    Diabetologia; 1993 Aug; 36(8):741-4. PubMed ID: 8405741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes.
    Meneilly GS; McIntosh CH; Pederson RA; Habener JF; Ehlers MR; Egan JM; Elahi D
    Diabetes Care; 2003 Mar; 26(3):837-42. PubMed ID: 12610046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes.
    Meneilly GS; Greig N; Tildesley H; Habener JF; Egan JM; Elahi D
    Diabetes Care; 2003 Oct; 26(10):2835-41. PubMed ID: 14514588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 does not not acutely affect insulin sensitivity in healthy man.
    Orskov L; Holst JJ; Møller J; Orskov C; Møller N; Alberti KG; Schmitz O
    Diabetologia; 1996 Oct; 39(10):1227-32. PubMed ID: 8897012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
    Nauck MA; Heimesaat MM; Orskov C; Holst JJ; Ebert R; Creutzfeldt W
    J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes.
    Vella A; Shah P; Basu R; Basu A; Camilleri M; Schwenk FW; Holst JJ; Rizza RA
    Diabetes; 2001 Mar; 50(3):565-72. PubMed ID: 11246876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations in non-insulin-mediated glucose uptake in the elderly patient with diabetes.
    Forbes A; Elliott T; Tildesley H; Finegood D; Meneilly GS
    Diabetes; 1998 Dec; 47(12):1915-9. PubMed ID: 9836524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
    Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
    Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide.
    Elahi D; Egan JM; Shannon RP; Meneilly GS; Khatri A; Habener JF; Andersen DK
    Obesity (Silver Spring); 2008 Jul; 16(7):1501-9. PubMed ID: 18421270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus.
    Mannucci E; Ognibene A; Cremasco F; Bardini G; Mencucci A; Pierazzuoli E; Ciani S; Fanelli A; Messeri G; Rotella CM
    Diabet Med; 2000 Oct; 17(10):713-9. PubMed ID: 11110504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impairment of noninsulin-mediated glucose disposal in the elderly.
    Meneilly GS; Elahi D; Minaker KL; Sclater AL; Rowe JW
    J Clin Endocrinol Metab; 1989 Mar; 68(3):566-71. PubMed ID: 2563735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.
    Knop FK; Vilsbøll T; Larsen S; Madsbad S; Holst JJ; Krarup T
    Diabetes Care; 2003 Sep; 26(9):2581-7. PubMed ID: 12941722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.